Geron Corporation (0IV3.L)
USD 3.93
(-1.38%)
USD 3.93
(-1.38%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 237 Thousand USD | -60.23% |
| 2022 | 596 Thousand USD | -57.21% |
| 2021 | 1.39 Million USD | 450.59% |
| 2020 | 253 Thousand USD | -45.0% |
| 2019 | 460 Thousand USD | -56.85% |
| 2018 | 1.06 Million USD | 0.09% |
| 2017 | 1.06 Million USD | -82.72% |
| 2016 | 6.16 Million USD | -83.06% |
| 2015 | 36.37 Million USD | 3054.47% |
| 2014 | 1.15 Million USD | -10.13% |
| 2013 | 1.28 Million USD | -52.64% |
| 2012 | 2.7 Million USD | 11.12% |
| 2011 | 2.43 Million USD | -31.57% |
| 2010 | 3.56 Million USD | 106.43% |
| 2009 | 1.72 Million USD | -38.42% |
| 2008 | 2.8 Million USD | -63.22% |
| 2007 | 7.62 Million USD | 132.59% |
| 2006 | 3.27 Million USD | 1030.0% |
| 2005 | 290 Thousand USD | -72.46% |
| 2004 | 1.05 Million USD | -10.31% |
| 2003 | 1.17 Million USD | -5.93% |
| 2002 | 1.24 Million USD | -65.52% |
| 2001 | 3.62 Million USD | -45.23% |
| 2000 | 6.6 Million USD | 22.39% |
| 1999 | 5.4 Million USD | -20.59% |
| 1998 | 6.8 Million USD | -6.85% |
| 1997 | 7.3 Million USD | 37.74% |
| 1996 | 5.3 Million USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 882 Thousand USD | 190.13% |
| 2024 Q1 | 304 Thousand USD | 1221.74% |
| 2023 Q3 | 164 Thousand USD | 465.52% |
| 2023 Q1 | 21 Thousand USD | -79.61% |
| 2023 Q4 | 23 Thousand USD | -85.98% |
| 2023 Q2 | 29 Thousand USD | 38.1% |
| 2023 FY | 237 Thousand USD | -60.23% |
| 2022 FY | 596 Thousand USD | -57.21% |
| 2022 Q1 | 123 Thousand USD | -88.17% |
| 2022 Q2 | 73 Thousand USD | -40.65% |
| 2022 Q3 | 297 Thousand USD | 306.85% |
| 2022 Q4 | 103 Thousand USD | -65.32% |
| 2021 Q2 | 107 Thousand USD | -21.9% |
| 2021 Q1 | 137 Thousand USD | 174.0% |
| 2021 Q3 | 109 Thousand USD | 1.87% |
| 2021 FY | 1.39 Million USD | 450.59% |
| 2021 Q4 | 1.04 Million USD | 854.13% |
| 2020 Q3 | 108 Thousand USD | 151.16% |
| 2020 Q1 | 52 Thousand USD | -69.59% |
| 2020 FY | 253 Thousand USD | -45.0% |
| 2020 Q2 | 43 Thousand USD | -17.31% |
| 2020 Q4 | 50 Thousand USD | -53.7% |
| 2019 Q3 | 131 Thousand USD | 29.7% |
| 2019 FY | 460 Thousand USD | -56.85% |
| 2019 Q1 | 57 Thousand USD | -84.8% |
| 2019 Q2 | 101 Thousand USD | 77.19% |
| 2019 Q4 | 171 Thousand USD | 30.53% |
| 2018 Q1 | 318 Thousand USD | 66.49% |
| 2018 Q2 | 208 Thousand USD | -34.59% |
| 2018 Q3 | 165 Thousand USD | -20.67% |
| 2018 Q4 | 375 Thousand USD | 127.27% |
| 2018 FY | 1.06 Million USD | 0.09% |
| 2017 FY | 1.06 Million USD | -82.72% |
| 2017 Q1 | 537 Thousand USD | 471.28% |
| 2017 Q3 | 163 Thousand USD | -6.32% |
| 2017 Q2 | 174 Thousand USD | -67.6% |
| 2017 Q4 | 191 Thousand USD | 17.18% |
| 2016 Q3 | 5.1 Million USD | 2320.85% |
| 2016 Q1 | 749 Thousand USD | 240.45% |
| 2016 Q4 | 94 Thousand USD | -98.16% |
| 2016 FY | 6.16 Million USD | -83.06% |
| 2016 Q2 | 211 Thousand USD | -71.83% |
| 2015 Q1 | 537 Thousand USD | 201.69% |
| 2015 FY | 36.37 Million USD | 3054.47% |
| 2015 Q3 | 35.36 Million USD | 13988.84% |
| 2015 Q2 | 251 Thousand USD | -53.26% |
| 2015 Q4 | 220 Thousand USD | -99.38% |
| 2014 FY | 1.15 Million USD | -10.13% |
| 2014 Q4 | 178 Thousand USD | 11.25% |
| 2014 Q3 | 160 Thousand USD | -53.08% |
| 2014 Q1 | 474 Thousand USD | 110.67% |
| 2014 Q2 | 341 Thousand USD | -28.06% |
| 2013 Q2 | 112 Thousand USD | -85.36% |
| 2013 Q1 | 765 Thousand USD | 11.03% |
| 2013 FY | 1.28 Million USD | -52.64% |
| 2013 Q4 | 225 Thousand USD | 24.31% |
| 2013 Q3 | 181 Thousand USD | 61.61% |
| 2012 Q2 | 130 Thousand USD | -89.63% |
| 2012 Q3 | 636 Thousand USD | 389.23% |
| 2012 Q4 | 689 Thousand USD | 8.33% |
| 2012 FY | 2.7 Million USD | 11.12% |
| 2012 Q1 | 1.25 Million USD | 399.6% |
| 2011 Q2 | 462 Thousand USD | -69.3% |
| 2011 FY | 2.43 Million USD | -31.57% |
| 2011 Q4 | 251 Thousand USD | 14.09% |
| 2011 Q1 | 1.5 Million USD | 37.07% |
| 2011 Q3 | 220 Thousand USD | -52.38% |
| 2010 Q1 | 918 Thousand USD | 51.74% |
| 2010 FY | 3.56 Million USD | 106.43% |
| 2010 Q4 | 1.09 Million USD | 101.1% |
| 2010 Q3 | 546 Thousand USD | -45.45% |
| 2010 Q2 | 1 Million USD | 9.04% |
| 2009 Q4 | 605 Thousand USD | 22.47% |
| 2009 Q2 | 183 Thousand USD | -58.78% |
| 2009 Q1 | 444 Thousand USD | -18.38% |
| 2009 FY | 1.72 Million USD | -38.42% |
| 2009 Q3 | 494 Thousand USD | 169.95% |
| 2008 Q4 | 544 Thousand USD | 48.23% |
| 2008 Q2 | 198 Thousand USD | -88.31% |
| 2008 FY | 2.8 Million USD | -63.22% |
| 2008 Q3 | 367 Thousand USD | 85.35% |
| 2008 Q1 | 1.69 Million USD | -63.86% |
| 2007 Q2 | 889 Thousand USD | -2.95% |
| 2007 Q4 | 4.68 Million USD | 314.78% |
| 2007 FY | 7.62 Million USD | 132.59% |
| 2007 Q1 | 916 Thousand USD | -22.7% |
| 2007 Q3 | 1.13 Million USD | 27.11% |
| 2006 Q4 | 1.18 Million USD | 63.9% |
| 2006 FY | 3.27 Million USD | 1030.0% |
| 2006 Q3 | 723 Thousand USD | -8.02% |
| 2006 Q2 | 786 Thousand USD | 34.82% |
| 2006 Q1 | 583 Thousand USD | 111.4% |
| 2005 Q2 | 4.67 Million USD | 7816.95% |
| 2005 Q4 | -5.11 Million USD | -859.73% |
| 2005 FY | 290 Thousand USD | -72.46% |
| 2005 Q1 | 59 Thousand USD | -82.54% |
| 2005 Q3 | 673 Thousand USD | -85.59% |
| 2004 Q2 | 366 Thousand USD | 47.58% |
| 2004 Q3 | 101 Thousand USD | -72.4% |
| 2004 Q1 | 248 Thousand USD | 60.0% |
| 2004 FY | 1.05 Million USD | -10.31% |
| 2004 Q4 | 338 Thousand USD | 234.65% |
| 2003 Q3 | 472 Thousand USD | 65.61% |
| 2003 Q1 | 36 Thousand USD | -87.71% |
| 2003 Q2 | 285 Thousand USD | 691.67% |
| 2003 Q4 | 155 Thousand USD | -67.16% |
| 2003 FY | 1.17 Million USD | -5.93% |
| 2002 Q2 | 111 Thousand USD | -78.45% |
| 2002 Q3 | 218 Thousand USD | 96.4% |
| 2002 Q4 | 293 Thousand USD | 34.4% |
| 2002 Q1 | 515 Thousand USD | -17.34% |
| 2002 FY | 1.24 Million USD | -65.52% |
| 2001 Q2 | 585 Thousand USD | -67.45% |
| 2001 FY | 3.62 Million USD | -45.23% |
| 2001 Q4 | 623 Thousand USD | 1.3% |
| 2001 Q3 | 615 Thousand USD | 5.13% |
| 2001 Q1 | 1.79 Million USD | 1.76% |
| 2000 Q1 | 1.27 Million USD | -2.23% |
| 2000 Q4 | 1.76 Million USD | -1.67% |
| 2000 Q3 | 1.79 Million USD | 1.13% |
| 2000 FY | 6.6 Million USD | 22.39% |
| 2000 Q2 | 1.77 Million USD | 39.73% |
| 1999 Q3 | 1.3 Million USD | 0.0% |
| 1999 Q2 | 1.3 Million USD | -13.33% |
| 1999 FY | 5.4 Million USD | -20.59% |
| 1999 Q1 | 1.5 Million USD | 0.0% |
| 1999 Q4 | 1.3 Million USD | 0.0% |
| 1998 Q3 | 1.5 Million USD | 0.0% |
| 1998 Q4 | 1.5 Million USD | 0.0% |
| 1998 Q2 | 1.5 Million USD | -34.78% |
| 1998 Q1 | 2.3 Million USD | -17.86% |
| 1998 FY | 6.8 Million USD | -6.85% |
| 1997 Q1 | 100 Thousand USD | -88.89% |
| 1997 Q4 | 2.8 Million USD | 27.27% |
| 1997 FY | 7.3 Million USD | 37.74% |
| 1997 Q3 | 2.2 Million USD | 0.0% |
| 1997 Q2 | 2.2 Million USD | 2100.0% |
| 1996 Q2 | 1.6 Million USD | 23.08% |
| 1996 FY | 5.3 Million USD | 0.0% |
| 1996 Q4 | 900 Thousand USD | -40.0% |
| 1996 Q3 | 1.5 Million USD | -6.25% |
| 1996 Q1 | 1.3 Million USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Editas Medicine, Inc. | 78.12 Million USD | 99.697% |
| Dynavax Technologies Corporation | 232.28 Million USD | 99.898% |
| Supernus Pharmaceuticals, Inc. | 607.52 Million USD | 99.961% |
| Perrigo Company plc | 4.65 Billion USD | 99.995% |
| Illumina, Inc. | 4.5 Billion USD | 99.995% |
| Thermo Fisher Scientific Inc. | 42.85 Billion USD | 99.999% |
| Iovance Biotherapeutics, Inc. | 1.18 Million USD | 80.067% |
| Walgreens Boots Alliance, Inc. | 147.65 Billion USD | 100.0% |
| IQVIA Holdings Inc. | 14.98 Billion USD | 99.998% |
| Heron Therapeutics, Inc. | 127.04 Million USD | 99.813% |
| Regeneron Pharmaceuticals, Inc. | 13.11 Billion USD | 99.998% |
| Unity Biotechnology, Inc. | - USD | -Infinity% |
| Waters Corporation | 2.95 Billion USD | 99.992% |
| Biogen Inc. | 9.83 Billion USD | 99.998% |
| Sangamo Therapeutics, Inc. | 176.23 Million USD | 99.866% |
| Evolus, Inc. | 202.08 Million USD | 99.883% |
| Adicet Bio, Inc. | - USD | -Infinity% |
| Cara Therapeutics, Inc. | 20.96 Million USD | 98.87% |
| bluebird bio, Inc. | 29.49 Million USD | 99.197% |
| Esperion Therapeutics, Inc. | 116.33 Million USD | 99.796% |
| FibroGen, Inc. | 147.75 Million USD | 99.84% |
| Agilent Technologies, Inc. | 6.83 Billion USD | 99.997% |
| Corbus Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Homology Medicines, Inc. | -6.65 Million USD | 103.563% |
| Alnylam Pharmaceuticals, Inc. | 1.82 Billion USD | 99.987% |
| Amicus Therapeutics, Inc. | 399.35 Million USD | 99.941% |
| Myriad Genetics, Inc. | 678.4 Million USD | 99.965% |
| Viking Therapeutics, Inc. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | 36.27 Million USD | 99.347% |
| Zoetis Inc. | 8.54 Billion USD | 99.997% |
| Abeona Therapeutics Inc. | 3.5 Million USD | 93.229% |
| Mettler-Toledo International Inc. | 3.78 Billion USD | 99.994% |
| BioMarin Pharmaceutical Inc. | 2.41 Billion USD | 99.99% |
| Vertex Pharmaceuticals Incorporated | 9.86 Billion USD | 99.998% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| Ionis Pharmaceuticals, Inc. | 787.64 Million USD | 99.97% |
| Atara Biotherapeutics, Inc. | 8.57 Million USD | 97.236% |
| Verastem, Inc. | - USD | -Infinity% |
| Nektar Therapeutics | 90.12 Million USD | 99.737% |
| Axsome Therapeutics, Inc. | 270.6 Million USD | 99.912% |
| Aclaris Therapeutics, Inc. | 31.24 Million USD | 99.242% |
| Sarepta Therapeutics, Inc. | 1.24 Billion USD | 99.981% |
| OPKO Health, Inc. | 863.49 Million USD | 99.973% |
| Exelixis, Inc. | 1.83 Billion USD | 99.987% |
| Neurocrine Biosciences, Inc. | 1.88 Billion USD | 99.987% |
| Corcept Therapeutics Incorporated | 482.37 Million USD | 99.951% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| uniQure N.V. | 15.84 Million USD | 98.504% |
| Imunon, Inc. | - USD | -Infinity% |
| Blueprint Medicines Corporation | 249.38 Million USD | 99.905% |
| Insmed Incorporated | 305.2 Million USD | 99.922% |
| Halozyme Therapeutics, Inc. | 829.25 Million USD | 99.971% |
| Agios Pharmaceuticals, Inc. | 26.82 Million USD | 99.116% |
| TG Therapeutics, Inc. | 233.66 Million USD | 99.899% |
| Incyte Corporation | 3.69 Billion USD | 99.994% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | 99.977% |